Chimerix (Chimerix) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 23, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Chimerix EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Chimerix's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Chimerix's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Chimerix's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimerix's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Chimerix's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Chimerix (NAS:CMRX) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Chimerix EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Chimerix's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimerix (Chimerix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (NAS:CMRX) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

CXF:Germany CXF:Germany

Address

2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713

Website

https://www.chimerix.com

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.

Executives

Fred A Middleton	director	400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
David Jakeman	officer: Principal Accounting Officer	C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Michael A. Sherman	director, officer: Chief Executive Officer	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Michael T. Andriole	officer: Chief Business Officer	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Cantex Pharmaceuticals, Inc.	10 percent owner	1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326
Victoria Vakiener	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Allen S. Melemed	officer: Chief Medical Officer	C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Pratik S Multani	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
William Garrett Nichols	officer: Chief Medical Officer	C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Michael Albert Alrutz	officer: Principal Executive Officer	2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713
M Michelle Berrey	officer: Chief Medical Officer	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Ed Greissing	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713